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Abstract
Introduction Despite the current standard of care, patients
with cardiovascular disease remain at a high risk for
recurrent events. Inhibition of thrombin-mediated platelet
activation through protease-activated receptor-1 antago-
nism may provide reductions in atherosclerotic disease
beyond those achievable with the current standard of care.
Objective Our primary objective is to evaluate the clinical
literature regarding the role of vorapaxar (ZontivityTM) in
the reduction of cardiovascular events in patients with a
history of myocardial infarction and peripheral artery dis-
ease. In particular, we focus on the potential future direc-
tions for protease-activating receptor antagonists in the
treatment of a broad range of atherosclerotic diseases.
Data Sources A literature search of PubMed and EBSCO
was conducted to identify randomized clinical trials from
August 2005 to June 2016 using the search terms: ‘vora-
paxar’, ‘SCH 530348’, ‘protease-activated receptor-1
antagonist’, and ‘ZontivityTM’. Bibliographies were sear-
ched and additional resources were obtained.
Results Vorapaxar is a first-in-class, protease-activated
receptor-1 antagonist. The Thrombin Receptor Antagonist
for Clinical Event Reduction (TRACER) trial did not
demonstrate a significant reduction in a broad primary
composite endpoint. However, the Thrombin-Receptor
Antagonist in Secondary Prevention of Atherothrombotic
Ischemic Events (TRA 2P-TIMI 50) trial examined a
more traditional composite endpoint and found a signifi-
cant benefit with vorapaxar. Vorapaxar significantly
increased bleeding compared with standard care. Ongoing
trials will help define the role of vorapaxar in patients with
peripheral arterial disease, patients with diabetes mellitus,
and other important subgroups. The use of multivariate
modeling may enable the identification of subgroups with
maximal benefit and minimal harm from vorapaxar.
Conclusion Vorapaxar provides clinicians with a novel
mechanism of action to further reduce the burden of
ischemic heart disease. Identification of patients with a
high ischemic risk and low bleeding risk would enable
clinicians to maximize the utility of this unique agent.
Key Points
Vorapaxar is a novel, first-in-class, protease-
activated receptor-1 antagonist.
Vorapaxar may provide incremental protection
against thrombotic cardiovascular events beyond the
standard of care.
Ongoing studies will help define the ideal patient
populations for protease-activated receptor
antagonism.
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article (doi:10.1007/s40268-016-0158-4) contains supplementary
material, which is available to authorized users.
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1 Introduction
Cardiovascular diseases (CVDs) represent a significant
global public health problem. According to the World
Health Organization, CVDs are the world’s leading cause
of death and disability. Currently, 17 million deaths are
attributable to cardiovascular events (CVEs) annually [1].
Of those, over 75% have atherothrombosis as an underly-
ing pathophysiology: 7.3 million due to ischemic heart
disease and 6.2 million due to strokes. Even with early
revascularization and potent dual antiplatelet therapy,
residual mortality remains high [2]. As a result, assessment
of new antiplatelet agents is an expanding research area.
Platelets play a major role in primary hemostasis, vas-
cular repair, and formation of pathogenic thrombi. Inhibi-
tion of platelet activation by aspirin and adenosine
diphosphate (ADP) receptor antagonists decreases platelet
aggregation and thus decreases CVEs (Online Fig. 1) [3].
These agents show long-term benefits in secondary pre-
vention but are associated with increased bleeding, and the
rate of recurrent ischemic events remains high. Targeting
the protease-activated receptor-1 (PAR-1) found on human
platelets provides a promising new mechanism to block
platelet activation and decrease the residual risk of CVEs.
Vorapaxar, a first in its class, is an orally available PAR-1
antagonist approved for the reduction of CVEs in patients with
a history of myocardial infarction (MI) or with peripheral
arterial disease (PAD). Vorapaxar reduced the rate of the
combined endpoint of cardiovascular death, stroke, and MI in
one of two phase III trials [4, 5]. However, coupled to this
reduction in the primary endpoint is the increased risk of
bleeding. This article outlines the effects of vorapaxar on
ischemic and bleeding outcomes as well as its potentially
novel roles in the treatment of atherosclerotic disease.
2 Data Sources
A literature search of PubMed, IPA, OneSearch, and MED-
LINE was conducted from June 2008 to June 2016. The search
terms ‘vorapaxar’, ‘SCH 530348’, ‘protease-activated recep-
tor-1 antagonist’, and ‘ZontivityTM’ were used. Studies pub-
lished in English evaluating vorapaxar were reviewed with an
emphasis on randomized controlled trials. Citations from
available articles were retrieved for additional references.
3 Pharmacology
Thrombin, a serine protease, facilitates hemostasis via
multiple actions including platelet activation, protein C
activation, and conversion of fibrinogen to fibrin. Thrombin
is the most potent circulating activator of platelets and
mediates these effects primarily through activation of the
G-protein-coupled PAR-1 on the platelet surface [6–8].
Platelet activation through PAR-1 signaling results in
extracellular ADP release, which then acts in an autocrine
fashion to activate platelet ADP receptors, sustaining long-
term effects [9].
Vorapaxar (SCH50348) is a potent, oral, reversible
thrombin receptor antagonist, which selectively antago-
nizes the PAR-1 to prevent thrombin-mediated platelet
activation (Online Fig. 1). Selective PAR-1 blockade by
vorapaxar results in inhibition of thrombin-induced platelet
aggregation but does not appear to impact primary hemo-
static functions, including the formation of fibrin to stabi-
lize the platelet plug [10, 11].
4 Pharmacokinetics
In patients with non-ST-segment elevation acute coronary
syndromes (NSTE-ACS), vorapaxar rapidly achieves
C80% inhibition of thrombin receptor-activating, peptide-
induced platelet aggregation by 2 h [12, 13]. Owing to its
long half-life of 173–269 h, steady-state concentrations of
vorapaxar are reached approximately 21 days after initial
dosing and platelet inhibition is sustained for[4 months.
Vorapaxar pharmacokinetic parameters are unaffected
by food consumption [14, 15]. No dosage adjustment is
needed for patients with end-stage renal failure [16]. While
no dosage adjustment is recommended for mild to mod-
erate hepatic impairment, vorapaxar is not recommended in
patients with severe hepatic failure owing to the increased
inherent risk of bleeding in these patients [17, 18]. Vora-
paxar is hepatically metabolized by cytochrome P450
(CYP)3A4 and CYP2J2 enzymes, resulting in the forma-
tion of an active metabolite with equal potency to the
parent compound [19]. Vorapaxar is a weak inhibitor of
intestinal p-glycoprotein [20, 21]. Table 1 shows additional
pharmacokinetic parameters.
5 Drug Interactions
Pharmacokinetic drug interaction studies are few with
vorapaxar; however, because vorapaxar is metabolized by
CYP3A4 (alongside CYP2J2), drugs that are inducers or
inhibitors of CYP3A4 will potentially impact the elimina-
tion of vorapaxar. Co-administration of ketoconazole for
3 weeks increased vorapaxar exposure by twofold while
co-administration with rifampin reduced vorapaxar expo-
sure by 50% [22]. Thus, strong inducers or inhibitors of
CYP3A4 should be avoided. Additionally, dose adjust-
ments appear to be unnecessary for patients on CYP2C9/
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2C19 substrates [18]. It was determined that vorapaxar is
only a weak inhibitor of p-glycoprotein as evidenced by the
fact that vorapaxar had no impact on serum digoxin con-
centrations. Thus, no dose adjustment of digoxin is nec-
essary [21]. Concomitant use of vorapaxar and platelet
glycoprotein IIb–IIIa inhibitors should be limited because
of the potential for a pharmacodynamic drug interaction,
resulting in a heightened predisposition to bleeding [23].
6 Current Use of Vorapaxar
Vorapaxar is approved for the reduction of thrombotic
CVEs in patients with a history of MI or with PAD. The
current clinical use of vorapaxar is based on two large,
randomized clinical trials conducted in patients with a
broad range of vascular diseases. At present, vorapaxar has
limited clinical utility. Multivariate analyses will be
required to identify features of patients with a high
ischemic risk and low bleeding risk in whom vorapaxar
presents a net clinical benefit.
7 Clinical Trials Overview
The Thrombin Receptor Antagonist for Clinical Event
Reduction (TRACER) trial was a randomized, double-
blind, multinational trial comparing vorapaxar (40-mg
loading dose followed by 2.08 mg daily) with placebo, on a
background of standard antiplatelet therapy, in 12,944
patients with NSTE-ACS (Table 2) [4, 24].
The primary efficacy endpoint of death from cardio-
vascular causes, MI, stroke, recurrent ischemia with hos-
pitalization, or urgent coronary revascularization occurred
in 1031 of 6473 (18.5%) patients taking vorapaxar and in
1102 of 6371 (19.9%) patients receiving placebo (hazard
ratio [HR] 0.92; 95% confidence interval [CI] 0.85–1.01;





Mean Cmax 23.7 ng/mL 19.4 ng/mL
Mean AUC0–72 h 323 ngh/mL 313 ngh/mL
Median Tmax 1.25 h 2.00 h
Distribution [15, 19]
Mean Vd/F 508 L
Plasma protein binding C99%
Metabolism [18, 19]
Primary metabolites
Metabolites produced: M19  M20
M19: inactive amine metabolite formed by carbamate cleavage
M20: hydroxylated metabolite equipotent with vorapaxar
Hepatic isoenzymes
CYP3A4
Major CYP enzyme responsible for M19 formation
Primary metabolite of vorapaxar is the M19 metabolite (&80% of exposure)
CYP2J2 and CYP3A4
Responsible for the metabolism of vorapaxar to M20
Only becomes detectable after long-term administration of vorapaxar
Elimination
Metabolites eliminated primarily in feces and, to a much smaller extent, urine
No unchanged vorapaxar detectable in urine
Excretion
Mean CL/F [15] 1.66 L/h
Mean half-life [12] 173–269 h
AUC0–-72 h area under the plasma concentration–time curve from time 0 to 72 h, CL/F apparent total body
clearance, Cmax maximum plasma concentration, CYP cytochrome P450, Tmax time to maximum plasma
concentration, Vd/F apparent volume of distribution
a Values based on 2.08-mg tablet (equivalent to vorapaxar sulfate 2.50 mg)
b Fed state after a high-fat meal
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death from cardiovascular causes, MI, or stroke compared
with placebo (16.4 vs. 14.7%; HR 0.89; 95% CI 0.81–0.98;
p = 0.02). However, cautious interpretation of this sec-
ondary endpoint is warranted in light of the non-significant
difference in the primary endpoint.
Vorapaxar, in comparison with placebo, was associated
with a significantly increased risk of bleeding when added
to aspirin and a P2Y12 inhibitor (GUSTO combined mod-
erate and severe bleeding: 7.2% vorapaxar and 5.2% pla-
cebo, p\ 0.001; TIMI clinically significant bleeding: 20.2
vs. 11.7%, p\ 0.001). Importantly, intracranial bleeding
was increased fivefold in vorapaxar-treated patients com-
pared with placebo (1.1 vs. 0.2%, p\ 0.001). As a result of
this increased risk of intracranial bleeding, an interim
safety review in 2011 recommended discontinuation of the
trial 6 months prior to the originally planned end date.
The Thrombin-Receptor Antagonist in Secondary
Prevention of Atherothrombotic Ischemic Events (TRA
2P-TIMI 50) trial was a phase III, randomized, double-
blind, placebo-controlled, multinational clinical trial cre-
ated to evaluate the safety and efficacy of vorapaxar in
secondary prevention (Table 2) [5, 25]. There are several
important differences between TRACER and TRA 2P-
TIMI 50. While TRACER enrolled patients during the
acute phase, TRA 2P-TIMI 50 enrolled 26,449 patients
receiving standard care for a broad range of CVDs,
including coronary, cerebrovascular, and peripheral dis-
ease. Another notable difference between these two large
phase III trials is the study treatment dosing, as the loading
dose used in TRACER was omitted in TRA 2P-TIMI 50.
Last, the primary endpoint in TRA 2P-TIMI 50 was
truncated to the composite of cardiovascular death, non-
fatal MI, or nonfatal stroke and did not include recurrent
ischemia with re-hospitalization or urgent coronary revas-
cularization. Once the increased risk of intracranial
bleeding became apparent in the TRACER trial, study
Table 2 Phase III vorapaxar clinical trials
TRACER trial [4, 24] TRA 2P-TIMI 50 trial [5, 25]







At least 18 years old
Acute symptoms of coronary ischemia within 24 h prior to
hospitalization with at least one of the following: troponin I or T
level[ULN, creatine kinase MB level[ULN, new ST-segment
depression[0.1 mV, or transient ST-segment elevation
(\30 min)[0.1 mV in C2 contiguous leads. In addition, C1 of the
following:[55 years old, previous MI, PCI, CABG, DM, or PAD
At least 18 years old
History of atherosclerosis involving the coronary,
cerebral, or peripheral vascular systems: CAD—
presumed spontaneous MI C2 weeks but B12 months
prior OR
Cerebrovascular disease—ischemic (presumed
thrombotic) C2 weeks but B12 months prior OR
PAD with a history of intermittent claudication with
either ankle-brachial index of\0.85 or previous




Concurrent or anticipated treatment with antithrombotics including
warfarin, factor Xa inhibitor, or direct thrombin inhibitor;
concurrent or anticipated treatment with a potent inducer or
inhibitor of CYP3A4 enzymes; active bleeding within the past
30 days; any history of intracranial hemorrhage; active
hepatobiliary disease; sustained severe hypertension
(SBP C200 mm Hg or DBP[100 mm Hg) within the previous
10 days; serious co-morbidity
Clinically unstable at time of enrollment; planned
coronary revascularization procedure; active bleeding
within the past 30 days; concurrent or anticipated
treatment with antithrombotics including warfarin,
factor Xa inhibitor, or direct thrombin inhibitor;
concurrent or anticipated treatment with a potent
inducer or inhibitor of CYP3A4 enzymes; any history
of intracranial hemorrhage; or active hepatobiliary
disease; sustained severe hypertension
(SBP C200 mm Hg or DBP[100 mm Hg) within the




Combination of death from CV causes, non-fatal MI, non-fatal stroke,
recurrent ischemia with rehospitalization, urgent coronary
revascularization





Combination of death from CV causes, non-fatal MI, non-fatal stroke Combination of death from CV causes, non-fatal MI,
non-fatal stroke, recurrent ischemia with
rehospitalization, urgent coronary revascularization
CABG coronary artery bypass grafting, CAD coronary artery disease, creatine kinase MB cardiac isozyme of creatine kinase, CV cardiovascular,
CYP cytochrome P450, DBP diastolic blood pressure, DM diabetes mellitus, Hg mercury, MI myocardial infarction, NSTE-ACE non-ST-segment
elevation acute coronary syndrome, PAD peripheral artery disease, PCI percutaneous coronary intervention, SBP systolic blood pressure,
TRACER Thrombin Receptor Antagonist for Clinical Event Reduction, TRA 2P-TIMI 50 Thrombin-Receptor Antagonist in Secondary
Prevention of Atherothrombotic Ischemic Events, UNL upper limit of normal
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treatment was discontinued in all TRA 2P-TIMI 50
patients with a prior stroke or transient ischemic attack.
Like TRACER, TRA 2P-TIMI 50 found a significant
reduction in the composite of cardiovascular death, non-
fatal MI, or nonfatal stroke with vorapaxar treatment (9.3
vs. 10.5%; HR 0.87; 95% CI 0.80–0.94; p\ 0.001) [5, 25].
However, this risk reduction was accompanied by an
increased risk of GUSTO moderate or severe bleeding (4.2
vs. 2.5%), TIMI clinically significant bleeding (15.8 vs.
11.1%), and intracranial hemorrhage (1.0 vs. 0.5%) in the
vorapaxar group (p\ 0.001 for all three assessments).
Together, TRACER and TRA 2P-TIMI 50 demonstrate
that vorapaxar, in addition to standard antiplatelet therapy,
provides an incremental risk reduction by targeting a novel
platelet activation pathway. These two trials also demon-
strate that triple antiplatelet therapy is accompanied by a
significant increase in the risk of bleeding. While the goals
of TRACER and TRA 2P-TIMI 50 were to demonstrate
the benefits of PAR-1 antagonism in a wide range of
patients, a net clinical benefit is unlikely to be achieved in
the majority of patients owing to the significant bleeding
risk of vorapaxar. However, subsequent re-analysis of well
curated data from these robust clinical trials has provided
insight into subgroups of patients whose risk of
atherosclerotic disease justifies the risk of bleeding (dia-
betes mellitus) or who lack effective treatment options
without vorapaxar (PAD). Interestingly, vorapaxar was
studied in the NSTE-ACS population, which is more
heterogeneous and at an overall lower risk than the STE-
ACS population. Furthermore, head-to-head comparisons
between vorapaxar and more potent P2Y12 antagonists
would be of considerable interest.
8 Future Directions: Potential Clinical Use
of Vorapaxar
Although the development of another PAR-1 antagonist,
atopaxar, has been discontinued, the TRACER and TRA
2P-TIMI 50 studies support a role for vorapaxar in a select
group of patients. Preliminary data suggest that multivari-
able modeling can be used to identify patients at a high
ischemic risk and low bleeding risk [26]. A meta-analysis
which combined phase II and III clinical trials investigated
the overall clinical effects of vorapaxar [27]. Overall,
reductions in MI were offset by a doubling in the risk of
intracranial hemorrhage. There was no significant differ-
ence in TIMI major bleeding or cardiovascular mortality.
However, several questions remain to be answered.
There is limited evidence on triple therapy with vorapaxar
in addition to aspirin and the more potent platelet antago-
nists, prasugrel and ticagrelor. Because of the significant
potential for bleeding, this combination therapy should be
avoided with few exceptions. Similarly, whether PAR-1
antagonism provides benefit in addition to extremely potent
ADP receptor inhibition is unknown. An ongoing phar-
macodynamic trial of 126 patients will provide initial data
on this combination of platelet antagonists [28].
Although TRA 2P-TIMI 50 demonstrated a significant
benefit in the reduction of recurrent ischemic events, the risk
of bleeding necessitates careful identification of candidates
for this very potent platelet inhibitor. The inclusion of a
heterogeneous cohort of coronary, cerebrovascular, and
PADs necessitates ‘‘teasing out’’, which subgroups derive
the most benefit and least harm with vorapaxar treatment. In
this section, we review the TRACER and TRA 2P-TIMI 50
to search for answers to these important questions.
8.1 Peripheral Artery Disease
Patients with PAD are not only at an increased risk for
acute limb-threatening events, but also for systemic man-
ifestations of atherosclerotic disease, such as cardiovascu-
lar death, MI, and ischemic stroke [29, 30]. In the TRA
2P-TIMI 50 trial, 3787 patients were diagnosed with PAD,
defined as a history of claudication and an ankle-brachial
index of\0.85 or prior revascularization for limb ischemia.
Although the primary composite endpoint (which included
coronary, cerebrovascular, and peripheral components) was
not significantly reduced in patients with PAD taking
vorapaxar, hospitalization as a result of acute limb ische-
mia and peripheral artery revascularization was signifi-
cantly reduced by vorapaxar (2.3% vorapaxar vs. 3.9%
placebo; p = 0.006 and 18.4% vorapaxar vs. 22.2% pla-
cebo; p = 0.017, respectively). This benefit was offset by a
significant increase in the risk of bleeding with vorapaxar
(7.4% vorapaxar vs. 4.5% placebo; p = 0.001) [30].
The TRACER trial did not purposefully target patients
with PAD and only 936 (7.2%) such patients were ran-
domized. While the event rates between vorapaxar and
placebo were not significantly different owing to the small
sample size, the overall profile of vorapaxar was similar to
that found in TRA 2P-TIMI 50: reduced peripheral
revascularization procedures and a lower extremity ampu-
tation rate (8.1 vs. 9.0%; p = 0.158 and 0.9 vs. 1.5%;
p = 0.107, respectively). Similarly, GUSTO moder-
ate/severe bleeding was increased with vorapaxar use in
patients with PAD (HR 1.47, 95% CI 0.89–2.45) but not to
a greater extent than patients without PAD (p-interac-
tion = 0.921) [31]. These results indicate that vorapaxar
may have a role in the treatment of PAD, given the lack of
effective therapies available. Although a small phase IV
trial is underway to evaluate vorapaxar in this setting, a
prospective study is likely required for vorapaxar to gain an
indication specifically for the prevention of acute limb
ischemia or peripheral revascularization [32].
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8.2 Diabetes Mellitus
Patients with diabetes, owing to their increased risk of
CVEs, may benefit from additional platelet inhibition with
vorapaxar to a greater extent than non-diabetic patients. In
diabetic patients (n = 3623) in TRA 2P-TIMI 50, the
primary endpoint of cardiovascular death, MI, or cere-
brovascular accident occurred more frequently than in non-
diabetic patients (n = 16,896) regardless of randomization
(14.1 vs. 7.4%; p\ 0.001) [33, 34]. However, diabetic
patients significantly benefited from additional antiplatelet
therapy with vorapaxar with respect to the primary com-
posite endpoint (12.6 vs. 15.7%; p = 0.004). GUSTO
moderate to severe bleeding was increased in diabetic
patients with vorapaxar vs. placebo (4.7 vs. 2.8%, HR 1.59,
95% CI 1.09–2.32; p = 0.02). The risk of GUSTO mod-
erate to severe bleeding was not different with vorapaxar in
diabetic and non-diabetic patients (p-interaction = 0.95).
An ongoing phase IV trial is designed to assess the effects
of vorapaxar in addition to dual antiplatelet therapy with
aspirin and clopidogrel compared with just dual antiplatelet
therapy alone in diabetic patients [35].
8.3 Coronary Artery Bypass Grafting
The increased risk of thrombotic complications following
coronary artery bypass grafting (CABG) can be attributed
to increased thrombin generation, which occurs both during
the procedure and continues after the procedure [36].
Whellan et al. proposed that PAR-1 antagonism could
reduce both graft occlusion and native coronary thrombosis
after CABG [37]. Among 1312 patients undergoing CABG
during the TRACER trial (vorapaxar, n = 639 and pla-
cebo, n = 673), vorapaxar significantly reduced ischemic
events compared with placebo (HR 0.55, 95% CI
0.36–0.83; p = 0.005). Bleeding related to CABG during
hospitalization did not differ significantly between vora-
paxar and placebo (GUSTO moderate to severe bleeding:
odds ratio 1.25, 95% CI 0.93–1.68; p = 0.13; TIMI major
bleeding: odds ratio 1.36, 95% CI 0.92–2.02; p = 0.12)
[4, 37]. Hence, in patients with NSTE-ACS undergoing
CABG, vorapaxar was associated with a significant
decrease in ischemic events. Notably, clopidogrel was used
in only 18% of patients undergoing CABG vs. 85% in non-
CABG. It is possible that the increase in bleeding events
was not seen in this subgroup owing to the infrequent use
of clopidogrel.
8.4 Stroke
Vorapaxar is strictly contraindicated in patients with a
history of stroke or transient ischemic attack because of a
significant increase in the risk of intracranial bleeding.
Among TRA 2P-TIMI 50 patients with prior stroke,
recurrent stroke was not reduced by vorapaxar (10.1%
vorapaxar vs. 7.5% placebo, HR 1.13, 95% CI 0.90–1.40;
p = 0.30), and GUSTO moderate or severe bleeding was
higher in the vorapaxar group (4.2% vorapaxar vs. 2.4%
placebo, HR 1.93, 95% CI 1.33–2.79; p\ 0.001) [5, 38].
Importantly, intracranial bleeding was significantly
increased in the vorapaxar group, including subdural or
epidural bleeding (2.5% vorapaxar vs. 1.0% placebo;
p\ 0.001). Fatal bleeding was numerically higher for
vorapaxar vs. placebo but not statistically significant (8 vs.
4; p = 0.26). However, a more recent study demonstrates
that vorapaxar may provide effective stroke prevention in
patients without a history of prior stroke [39].
8.5 Background Antiplatelet Therapy
Vorapaxar may have greater efficacy in patients treated
with aspirin alone compared with aspirin plus a P2Y12
inhibitor [4]. In TRACER patients treated with clopidogrel
(91.8% of all patients), the risk of GUSTO moderate or
severe bleeding was increased significantly compared with
those treated with aspirin alone (HR 0.95, 95% CI
0.65–1.40 with no thienopyridine and HR 1.45, 95% CI
1.23–1.71 with thienopyridine; p-interaction = 0.04)
[40, 41].
In TRA 2P-TIMI 50, dual antiplatelet therapy was less
common than in TRACER (58% of all patients) [42].
Thienopyridines were intentionally used in 15,256 patients
(58%) overall. There was no significant difference in the
reduction of the primary endpoint between vorapaxar with
thienopyridine and vorapaxar with no thienopyridine (p-
interaction = 0.64). Compared with TRACER, GUSTO
moderate to severe bleeding was increased with vorapaxar
in TRA 2P-TIMI 50, but there was no significant inter-
action based on current (p-interaction = 0.29) or prior (p-
interaction = 0.99) thienopyridine use. Vorapaxar
decreased the risk of CVD, MI, or stroke in stable patients
with a history of CVD with or without thienopyridines
[42, 43]. In both TRACER and TRA 2P-TIMI 50, few
patients were receiving more potent P2Y12 inhibition with
prasugrel or ticagrelor. The interaction between aspirin
dose and the efficacy and safety profile of vorapaxar was
investigated in both TRACER and TRA 2P-TIMI 50.
Aspirin dose did not modify the efficacy or safety profile
significantly in either study [4, 5].
Because vorapaxar has been documented to increase
bleeding risks, healthcare professionals must be cognizant
of a patient’s general underlying bleeding risk. General risk
factors for bleeding include older age, low body weight,
reduced renal or hepatic function, history of bleeding dis-
orders, and use of other drugs that impact the coagulation
pathways. Vorapaxar should be used cautiously or not at all
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in these patients. The patients who have a high ischemic
risk coupled with a low bleeding risk will benefit most
from the addition of vorapaxar to standard care [26].
9 Conclusion
The residual risk of atherosclerotic events in patients with
coronary, cerebrovascular, and PAD remains unacceptably
high, even after revascularization and treatment with potent
platelet ADP receptor antagonists. Vorapaxar, the only
available PAR-1 antagonist, may provide clinicians with an
effective treatment for patients with strong risk factors,
such as diabetes. Similarly, vorapaxar may represent a
novel approach to the treatment of PAD. The major limi-
tation to vorapaxar therapy is bleeding, as expected with
antiplatelet therapy. However, vorapaxar may meet the
requirements of patients who need additional therapy to
reduce the risk for CVEs.
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